Inventor · disambiguated record
David Suhy
Also filed as: SUHY DAVID · SUHY DAVID A
16 granted patents·16 pending applications·91 citations·filing 2004–2025
92Inventor score
Top patents by PatentIndex Score
32 records- 0194US8283461B2Multiple promoter expression cassettes for simultaneous delivery of RNAi agentsROELVINK PETRUS W·Filed 2010·Granted Oct 9, 2012·32 cites·10 claims
- 0290US7803611B2RNAi expression constructsBENITEC INC·Filed 2006·Granted Sep 28, 2010·10 cites·19 claims
- 0388US8993530B2RNAi expression constructsROELVINK PETRUS W·Filed 2011·Granted Mar 31, 2015·6 cites·6 claims
- 0487US8129510B2Minigene expression cassetteKAY MARK·Filed 2007·Granted Mar 6, 2012·13 cites·9 claims
- 0587US7727970B2Multiple promoter expression cassettes for simultaneous delivery of RNAi agents targeted to Hepatitis C virusBENITEC INC·Filed 2005·Granted Jun 1, 2010·9 cites·2 claims
- 0685US12060613B2Methods and compositions for synthetic biomarkersEARLI INC·Filed 2021·Granted Aug 13, 2024·2 cites·13 claims
- 0784US8008468B2RNAi expression constructs with liver-specific enhancer/promoterBENITEC INC·Filed 2006·Granted Aug 30, 2011·9 cites·16 claims
- 0883US11142765B2Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereofBENITEC BIOPHARMA LTD·Filed 2017·Granted Oct 12, 2021·3 cites·27 claims
- 0983US10898505B2Reagents for treatment of hepatitis B virus (HBV) infection and use thereofBENITEC BIOPHARMA LTD·Filed 2016·Granted Jan 26, 2021·3 cites·20 claims
- 1078US12448652B2Methods and compositions for synthetic biomarkersEARLI INC·Filed 2023·Granted Oct 21, 2025·0 cites·17 claims
- 1177US11535851B2Reagents for treatment of hepatitis B virus (HBV) infection and use thereofBENITEC BIOPHARMA LTD·Filed 2017·Granted Dec 27, 2022·1 cites·23 claims
- 1276US8076471B2RNAi expression constructsROELVINK PETRUS W·Filed 2006·Granted Dec 13, 2011·1 cites·24 claims
- 1375US2025064973A1Methods and compositions for synthetic biomarkersEARLI INC·Filed 2023·Application pending·0 cites
- 1467US2022275451A1Methods and compositions for synthetic biomarkersEARLI INC·Filed 2021·Application pending·0 cites
- 1565US10000753B2Age-related macular degeneration treatmentBENITEC BIOPHARMA LTD·Filed 2014·Granted Jun 19, 2018·1 cites·23 claims
- 1663US11234994B2Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereofBENITEC BIOPHARMA LTD·Filed 2017·Granted Feb 1, 2022·1 cites·21 claims
- 1762US2023093951A1Reagents for treatment of hepatitis b virus (hbv) infection and use thereofBENITEC IP HOLDINGS INC·Filed 2022·Application pending·0 cites
- 1861US11932852B2Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereofBENITEC IP HOLDINGS INC·Filed 2021·Granted Mar 19, 2024·0 cites·22 claims
- 1960US2021177885A1Reagents for treatment of hepatitis b virus (hbv) infection and use thereofBENITEC BIOPHARMA LTD·Filed 2020·Application pending·0 cites
- 2058US8691967B2Multiple promoter expression cassettes for simultaneous delivery of RNAi agentsBENITEC INC·Filed 2012·Granted Apr 8, 2014·0 cites·16 claims
- 2157US2025144249A1Methods using surface-expressible activatable epitopes to localize and/or treat diseased cellsEARLI INC·Filed 2024·Application pending·0 cites
- 2257US2015197751A1Rnai expression constructsBENITEC INC·Filed 2015·Application pending·0 cites
- 2352US2023056226A1Compositions and methods for treating neurofibromatic disordersNF2 THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2449US2005059044A1Double-stranded nucleic acidFiled 2004·Application pending·0 cites
- 2547US2022106594A1Methods for Treating Oculopharyngeal Muscular Dystrophy (OPMD)BENITEC BIOPHARMA LTD·Filed 2019·Application pending·0 cites
- 2645US2011117608A1Double-stranded nucleic acidBENITEC AUSTRALIA LTD·Filed 2010·Application pending·0 cites
- 2744US2018320180A1Age-related macular degeneration treatmentBENITEC BIOPHARMA LTD·Filed 2018·Application pending·0 cites
- 2842US2006127919A1Compositions and methods relating to cell adhesion molecule L1ABO ARIE·Filed 2005·Application pending·0 cites
- 2942US2009036315A1Device and methods for detecting and quantifying one or more target agentsANTARA BIOSCIENCES INC·Filed 2007·Application pending·0 cites
- 3041US2022098614A1Compositions and Methods for Treating Oculopharyngeal Muscular Dystrophy (OPMD)BENITEC IP HOLDINGS INC·Filed 2020·Application pending·0 cites
- 3137US2019309307A1REAGENTS FOR PRODUCING T-CELLS WITH NON-FUNCTIONAL T-CELL RECEPTORS (TCRs) COMPOSITIONS COMPRISING SAME AND USE THEREOFBENITEC BIOPHARMA LTD·Filed 2017·Application pending·0 cites
- 3236US2025161496A1Synthetic cancer-specific promotersEARLI INC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Suhy files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →